Crossject SA — SEC Form D Filing
Crossject SA filed an SEC Form D on June 5, 2026, reporting $10.26M raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- June 5, 2026
- Amount reported
- $10.26M
- Round stage
- Seed
- Industry
- Pharmaceuticals
- Website
- https://crossject.com/en/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: FRANCE
Problem
People with epilepsy, adrenal crisis, and anaphylaxis often face life-threatening situations where current treatments may be inadequate, such as refractory seizures in epilepsy patients and the need for immediate emergency treatment for anaphylaxis.
Solution
Crossject offers ZENEO®, a needle-free, pre-filled, single-use auto-injector intended for rapid delivery of emergency medications in critical situations, addressing issues with existing treatments by ensuring fast and safe administration.
Why now
The increasing prevalence of life-threatening emergencies requires innovative solutions for faster drug delivery.
Verdict
Investors supported Crossject at this moment because the growing demand for immediate emergency responses legitimized the need for needle-free technology, not because existing solutions demonstrated overwhelming efficacy or reliability. Their implicit bet was on the expectation that healthcare providers would swiftly adopt ZENEO® for its potential to improve patient outcomes during critical situations. However, the limited upside is tied to a crowded market of alternatives where differentiation might wane, and long-term adoption hinges on proving superior efficacy over traditional methods.
Source: SEC EDGAR Form D filing